Limited Submission Funding Opportunities – *updated 12/03/21*

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of $50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process
Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. *Name of the Principal Investigator with appropriate contact information*
2. *A descriptive title of the potential application*
3. *Brief description of the project*
4. *Brief description of why you specifically should be selected to receive institutional nomination for this award*

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/pa-files/PAR-21-312.html
MGH LOI Deadline: 12/06/21
NIH Application Deadline: 1/25/22

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

Limited Submission Funding Opportunities – *updated 12/03/21*

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on ***Curriculum Development***. This NHGRI R25 program offers to support the development of curricula for Master of Science (M.S.) degree programs in genomics, genomic medicine and/or genomic informatics for medical students. Specifically, this FOA will support the development of curriculum designed to be freely available, at no cost to the broader community to enhance training in genomics for medical students.

2. Centers for Agricultural Safety and Health (U54) – NEW!

https://grants.nih.gov/grants/guide/rfa-files/RFA-OH-22-002.html

MGH LOI Deadline: 12/08/21

NIH LOI Deadline: 12/17/21

NIH Application Deadline: 1/24/22

The National Institute for Occupational Safety and Health (NIOSH) within the Centers for Disease Control and Prevention (CDC) invites applications for the Centers for Agricultural Safety and Health (Ag Centers). These centers are expected to conduct high quality research and subsequently disseminate their findings and recommendations in audience appropriate products to contribute to improving the safety and health of agriculture, forestry, and fishing workers. Center structure should take advantage of diverse scientific resources and focus on local, regional, and/or national worker safety and health issues. Emphasis should be placed on the creation and implementation of evidence-based solutions that address important agricultural, forestry, and fishing safety and health problems. Centers should also use innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based solutions. Collaborations with other academic institutions, nonprofit organizations, and other occupational safety and health focused groups are expected. Applicants must concisely describe the occupational safety and health burden within their service area and directly link research and outreach activities to help alleviate the burden. Applicants should also clearly articulate the anticipated impacts of the proposed work, both during the project period and beyond.

3. SUNBEAM – Analysis and Bioinformatics Center (ABC) (UM1 Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-060.html

MGH LOI Deadline: 12/08/21

NIH LOI Deadline: 1/15/22

NIH Application Deadline: 2/15/22

The purpose of the SUNBEAM - Analysis and Bioinformatics Center (SUNBEAM-ABC) is to establish a mechanistic omics center to support the birth cohort study Systems Biology of Early Atopy (SUNBEAM). The center will assay biologic samples collected within the SUNBEAM cohort using omics and systems biology approaches to identify determinants of atopic disease, focusing on food allergy and atopic dermatitis (AD) in newborns, infants, and very young children. SUNBEAM-ABC will support the SUNBEAM birth cohort study by providing analytic infrastructure for a comprehensive understanding of molecular and cellular pathways that contribute to atopic disease development and to identify early predictive biomarkers.

Limited Submission Funding Opportunities – *updated 12/03/21*

4. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-060.html
MGH LOI Deadline: 12/15/21
NIH Application Deadline: 2/28/22

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates *proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.* Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial *or an ancillary clinical trial* as lead investigator, should apply to the companion FOAs (RFA-CA-21-061 or RFA-CA-21-062).

For your LOI to ECOR, please indicate the scientific area that you will be submitting under (Data Science, Cancer Control Science, or Other Sciences. In addition, please indicate the RFA that you will submit your application under.

5. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-061.html
MGH LOI Deadline: 12/15/21
NIH Application Deadline: 2/28/22

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.
This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-21-060).

For your LOI to ECOR, please indicate the scientific area that you will be submitting under (Data Science, Cancer Control Science, or Other Sciences. In addition, please indicate the RFA that you will submit your application under.

6. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required)

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-062.html

MGH LOI Deadline: 12/15/21

NIH Application Deadline: 2/28/22

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-21-060).

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA (RFA-CA-21-060).

For your LOI to ECOR, please indicate the scientific area that you will be submitting under (Data Science, Cancer Control Science, or Other Sciences. In addition, please indicate the RFA that you will submit your application under.